Our previous studies have shown that at the specific concentration employed in this study (0.05 μM), LY333531 effectively suppresses total PKC activity and protects the integrity and function of the BBB, composed of HBMECs, HAs and HPs, under laboratory settings of hyperglycaemia and ischaemia-reperfusion injury (Shao and Bayraktutan 2013, 2014; Mathur and Bayraktutan 2016). The gene discussed is PRRT2; the disease is Hyperglycemia.